Cipla’s subsidiary -- Cipla Technologies LLC and Pulmatrix, Inc., a clinical stage biopharmaceutical company has entered into a definitive agreement for the co-development and commercialization of Pulmazole (PUR1900) - an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
Following the Definitive Agreement, Cipla Technologies will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazole in relation to pulmonary indications to Cipla Technologies. Thereafter, both parties will equally share costs related to the future development and commercialization of Pulmazole, and equally share worldwide free cash flow from future sales of Pulmazole.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1528.20 |
Dr. Reddys Lab | 5872.35 |
Cipla | 1405.95 |
Zydus Lifesciences | 997.45 |
Lupin | 1638.40 |
View more.. |